| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | AGT; PH1; SPT; AGT1; SPAT; TLH6; AGXT1 |
| WB Predicted band size | 43 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human AGXT |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与IGFBP1抗体相关的代表性文献信息及摘要概括：
1. **文献名称**: "Development of monoclonal antibodies specific for IGFBP-1"
**作者**: Lewitt, M.S., et al.
**摘要**: 该研究报道了针对IGFBP1的单克隆抗体的开发，验证了其在Western blot和ELISA中的特异性，并证实其可用于检测血清及细胞培养液中的IGFBP1蛋白浓度。
2. **文献名称**: "Insulin-like growth factor-binding protein-1: role in diabetes mellitus"
**作者**: Westwood, M., et al.
**摘要**: 通过使用特异性IGFBP1抗体，研究发现妊娠糖尿病患者的胎盘组织中IGFBP1表达异常，提示其可能通过调节IGF信号通路参与糖代谢紊乱机制。
3. **文献名称**: "Antibody-based detection of IGFBP-1 in human tissues"
**作者**: Hills, R., et al.
**摘要**: 该文献系统比较了多种商业IGFBP1抗体在免疫组化中的应用，确定了两种高特异性抗体，并揭示了IGFBP1在肝、肾等器官中的差异性表达模式。
注：以上文献信息为示例性内容，实际引用时建议通过PubMed或Google Scholar核对原文信息及DOI编号。
**Background of IGFBP1 Antibody**
Insulin-like growth factor-binding protein 1 (IGFBP1) is a key modulator of insulin-like growth factors (IGFs), primarily regulating their bioavailability and activity in growth, metabolism, and cellular processes. Produced mainly in the liver and decidualized endometrium, IGFBP1 binds IGF-1 and IGF-2 with high affinity, influencing tissue-specific IGF signaling. Its expression is dynamically regulated by hormones (e.g., insulin, glucocorticoids) and metabolic conditions, with elevated levels observed in pregnancy, intrauterine growth restriction, and insulin-resistant states.
IGFBP1 antibodies are essential tools for studying its role in physiological and pathological contexts. These antibodies enable the detection and quantification of IGFBP1 in biological samples (e.g., serum, plasma, tissues) via techniques like ELISA, Western blotting, and immunohistochemistry. They help elucidate IGFBP1’s interactions with IGFs, post-translational modifications (e.g., phosphorylation, glycosylation), and proteolytic cleavage patterns. Clinically, IGFBP1 antibodies aid in diagnosing conditions like gestational diabetes and preeclampsia, where IGFBP1 levels correlate with disease progression.
Research also explores IGFBP1’s dual role as both an inhibitor and enhancer of IGF actions, depending on cellular context. Species-specific antibodies (e.g., human, murine) further support translational studies in metabolic and reproductive health models. Understanding IGFBP1 dynamics through antibody-based assays continues to advance therapeutic targeting and biomarker development.
×
